Genocea Biosciences (GNCA) Announces GEN-003 Phase 2b Met Primary Endpoint as Genital Herpes Treatment
Tweet Send to a Friend
Genocea Biosciences, Inc. (Nasdaq: GNCA) announced positive results from its ongoing Phase 2b trial evaluating a new Phase 3-ready formulation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
